IGFBP-4 tumor and serum levels are increased across all stages of epithelial ovarian cancer
<p>Abstract</p> <p>Background</p> <p>We sought to identify candidate serum biomarkers for the detection and surveillance of EOC. Based on RNA-Seq transcriptome analysis of patient-derived tumors, highly expressed secreted proteins were identified using a bioinformatic a...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2012-01-01
|
Series: | Journal of Ovarian Research |
Subjects: | |
Online Access: | http://www.ovarianresearch.com/content/5/1/3 |
id |
doaj-707079b7f9ed4cea862b144b048e2772 |
---|---|
record_format |
Article |
spelling |
doaj-707079b7f9ed4cea862b144b048e27722020-11-24T21:02:02ZengBMCJournal of Ovarian Research1757-22152012-01-0151310.1186/1757-2215-5-3IGFBP-4 tumor and serum levels are increased across all stages of epithelial ovarian cancerMosig Rebecca ALobl MollieSenturk EmirShah HardikCohen SamanthaChudin EugeneFruscio RobertMarchini SergioD'Incalci MaurizioSachidanandam RaviDottino PeterMartignetti John A<p>Abstract</p> <p>Background</p> <p>We sought to identify candidate serum biomarkers for the detection and surveillance of EOC. Based on RNA-Seq transcriptome analysis of patient-derived tumors, highly expressed secreted proteins were identified using a bioinformatic approach.</p> <p>Methods</p> <p>RNA-Seq was used to quantify papillary serous ovarian cancer transcriptomes. Paired end sequencing of 22 flash frozen tumors was performed. Sequence alignments were processed with the program ELAND, expression levels with ERANGE and then bioinformatically screened for secreted protein signatures. Serum samples from women with benign and malignant pelvic masses and serial samples from women during chemotherapy regimens were measured for IGFBP-4 by ELISA. Student's t Test, ANOVA, and ROC curves were used for statistical analysis.</p> <p>Results</p> <p>Insulin-like growth factor binding protein (IGFBP-4) was consistently present in the top 7.5% of all expressed genes in all tumor samples. We then screened serum samples to determine if increased tumor expression correlated with serum expression. In an initial discovery set of 21 samples, IGFBP-4 levels were found to be elevated in patients, including those with early stage disease and normal CA125 levels. In a larger and independent validation set (82 controls, 78 cases), IGFBP-4 levels were significantly increased (p < 5 × 10<sup>-5</sup>). IGFBP-4 levels were ~3× greater in women with malignant pelvic masses compared to women with benign masses. ROC sensitivity was 73% at 93% specificity (AUC 0.816). In women receiving chemotherapy, average IGFBP-4 levels were below the ROC-determined threshold and lower in NED patients compared to AWD patients.</p> <p>Conclusions</p> <p>This study, the first to our knowledge to use RNA-Seq for biomarker discovery, identified IGFBP-4 as overexpressed in ovarian cancer patients. Beyond this, these studies identified two additional intriguing findings. First, IGFBP-4 can be elevated in early stage disease without elevated CA125. Second, IGFBP-4 levels are significantly elevated with malignant versus benign disease. These findings provide the rationale for future validation studies.</p> http://www.ovarianresearch.com/content/5/1/3IGFBP-4epithelial ovarian cancerserum biomarkerRNA-Seqtranscriptome |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Mosig Rebecca A Lobl Mollie Senturk Emir Shah Hardik Cohen Samantha Chudin Eugene Fruscio Robert Marchini Sergio D'Incalci Maurizio Sachidanandam Ravi Dottino Peter Martignetti John A |
spellingShingle |
Mosig Rebecca A Lobl Mollie Senturk Emir Shah Hardik Cohen Samantha Chudin Eugene Fruscio Robert Marchini Sergio D'Incalci Maurizio Sachidanandam Ravi Dottino Peter Martignetti John A IGFBP-4 tumor and serum levels are increased across all stages of epithelial ovarian cancer Journal of Ovarian Research IGFBP-4 epithelial ovarian cancer serum biomarker RNA-Seq transcriptome |
author_facet |
Mosig Rebecca A Lobl Mollie Senturk Emir Shah Hardik Cohen Samantha Chudin Eugene Fruscio Robert Marchini Sergio D'Incalci Maurizio Sachidanandam Ravi Dottino Peter Martignetti John A |
author_sort |
Mosig Rebecca A |
title |
IGFBP-4 tumor and serum levels are increased across all stages of epithelial ovarian cancer |
title_short |
IGFBP-4 tumor and serum levels are increased across all stages of epithelial ovarian cancer |
title_full |
IGFBP-4 tumor and serum levels are increased across all stages of epithelial ovarian cancer |
title_fullStr |
IGFBP-4 tumor and serum levels are increased across all stages of epithelial ovarian cancer |
title_full_unstemmed |
IGFBP-4 tumor and serum levels are increased across all stages of epithelial ovarian cancer |
title_sort |
igfbp-4 tumor and serum levels are increased across all stages of epithelial ovarian cancer |
publisher |
BMC |
series |
Journal of Ovarian Research |
issn |
1757-2215 |
publishDate |
2012-01-01 |
description |
<p>Abstract</p> <p>Background</p> <p>We sought to identify candidate serum biomarkers for the detection and surveillance of EOC. Based on RNA-Seq transcriptome analysis of patient-derived tumors, highly expressed secreted proteins were identified using a bioinformatic approach.</p> <p>Methods</p> <p>RNA-Seq was used to quantify papillary serous ovarian cancer transcriptomes. Paired end sequencing of 22 flash frozen tumors was performed. Sequence alignments were processed with the program ELAND, expression levels with ERANGE and then bioinformatically screened for secreted protein signatures. Serum samples from women with benign and malignant pelvic masses and serial samples from women during chemotherapy regimens were measured for IGFBP-4 by ELISA. Student's t Test, ANOVA, and ROC curves were used for statistical analysis.</p> <p>Results</p> <p>Insulin-like growth factor binding protein (IGFBP-4) was consistently present in the top 7.5% of all expressed genes in all tumor samples. We then screened serum samples to determine if increased tumor expression correlated with serum expression. In an initial discovery set of 21 samples, IGFBP-4 levels were found to be elevated in patients, including those with early stage disease and normal CA125 levels. In a larger and independent validation set (82 controls, 78 cases), IGFBP-4 levels were significantly increased (p < 5 × 10<sup>-5</sup>). IGFBP-4 levels were ~3× greater in women with malignant pelvic masses compared to women with benign masses. ROC sensitivity was 73% at 93% specificity (AUC 0.816). In women receiving chemotherapy, average IGFBP-4 levels were below the ROC-determined threshold and lower in NED patients compared to AWD patients.</p> <p>Conclusions</p> <p>This study, the first to our knowledge to use RNA-Seq for biomarker discovery, identified IGFBP-4 as overexpressed in ovarian cancer patients. Beyond this, these studies identified two additional intriguing findings. First, IGFBP-4 can be elevated in early stage disease without elevated CA125. Second, IGFBP-4 levels are significantly elevated with malignant versus benign disease. These findings provide the rationale for future validation studies.</p> |
topic |
IGFBP-4 epithelial ovarian cancer serum biomarker RNA-Seq transcriptome |
url |
http://www.ovarianresearch.com/content/5/1/3 |
work_keys_str_mv |
AT mosigrebeccaa igfbp4tumorandserumlevelsareincreasedacrossallstagesofepithelialovariancancer AT loblmollie igfbp4tumorandserumlevelsareincreasedacrossallstagesofepithelialovariancancer AT senturkemir igfbp4tumorandserumlevelsareincreasedacrossallstagesofepithelialovariancancer AT shahhardik igfbp4tumorandserumlevelsareincreasedacrossallstagesofepithelialovariancancer AT cohensamantha igfbp4tumorandserumlevelsareincreasedacrossallstagesofepithelialovariancancer AT chudineugene igfbp4tumorandserumlevelsareincreasedacrossallstagesofepithelialovariancancer AT frusciorobert igfbp4tumorandserumlevelsareincreasedacrossallstagesofepithelialovariancancer AT marchinisergio igfbp4tumorandserumlevelsareincreasedacrossallstagesofepithelialovariancancer AT dincalcimaurizio igfbp4tumorandserumlevelsareincreasedacrossallstagesofepithelialovariancancer AT sachidanandamravi igfbp4tumorandserumlevelsareincreasedacrossallstagesofepithelialovariancancer AT dottinopeter igfbp4tumorandserumlevelsareincreasedacrossallstagesofepithelialovariancancer AT martignettijohna igfbp4tumorandserumlevelsareincreasedacrossallstagesofepithelialovariancancer |
_version_ |
1716776850695389184 |